Development of Microparticles for Enhanced Embolization Therapies

用于增强栓塞治疗的微粒的开发

• 批准号: 488457-2015
• 负责人: Brooks, MarianneSuLing
• 金额: $ 1.82万
• 依托单位: Dalhousie University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=586260
• 关键词: Development; Microparticles; Enhanced; Embolization; Therapies

The development of novel biomaterials for medical applications is a challenge that requires advanced manufacturing techniques. For example, specialized microparticles have the potential to substantially improve the treatment of diseases such as hepatocellular carcinoma (HCC). Microparticles enable localized therapies such as transarterial chemoembolization (TACE) to be used in cases where the disease has been diagnosed at an advanced stage and surgical treatment is not possible. In TACE therapy, which is a minimally-invasive alternative to surgery, microparticles are utilized as embolic agents. The particles prevent blood flow to tumors and can also function as a targeted drug delivery system, when preloaded with a suitable drug. The proposed research is in collaboration with ABK Biomedical Inc., a dynamic medical device start-up company based in Nova Scotia. They are currently pursuing the development of embolic agents to treat cancers such as HCC. ABK's products are based on a novel radiopaque embolic bead platform that will enable clinicians to visually monitor the embolic site both during and post-procedure. They are seeking to extend their range of TACE products by developing advanced manufacturing techniques for the following novel biomaterials: (1) polymer-coated glass embolic microspheres to facilitate drug-delivery and (2) polymer-blend embolic microspheres. Dr. Brooks' research team at Dalhousie University will investigate advanced manufacturing techniques for the development of a suitable polymer-coating for the glass microspheres and new polymer-blends for synthesizing radiopaque embolic microspheres.

用于医疗应用的新型生物材料的开发是一项挑战，需要先进的 制造技术。例如，专门的微粒有可能大大改善 肝细胞癌（HCC）等疾病的治疗。微粒使局部治疗成为可能 如经动脉化疗栓塞术（TACE），用于在以下情况下诊断疾病： 晚期不可能进行手术治疗。在TACE治疗中，这是一种微创的 作为外科手术的替代，微粒被用作栓塞剂。这些颗粒阻止血液流向肿瘤 并且当预装载有合适的药物时，还可以用作靶向药物递送系统。 这项拟议中的研究是与ABK生物医学公司合作进行的，动态医疗器械启动 位于新斯科舍省的公司。他们目前正在开发栓塞剂来治疗癌症 例如肝细胞癌。ABK的产品基于一种新型的不透射线的栓塞珠平台， 临床医生在手术期间和术后对栓塞部位进行目视监测。他们正在寻求扩大他们的 通过开发先进的制造技术， 生物材料：（1）聚合物涂层的玻璃栓塞微球，以促进药物递送和（2）聚合物共混物 栓塞微球。布鲁克斯博士在达尔豪西大学的研究小组将调查先进的 用于开发玻璃微球的合适聚合物涂层的制造技术， 用于合成不透射线栓塞微球的新聚合物共混物。